Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ProBioGen, ImmunOs Ink Manufacturing Services Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

ProBioGen, ImmunOs Ink Manufacturing Services Agreement

ProBioGen will support ImmunOs in the development of their biologics using its DirectedLuck Transposase technology

By: Tiffany Coppolino

ProBioGen AG, together with ImmunOs Therapeutics AG, signed a manufacturing services agreement for ImmunOs’ novel platform of multitasking biologics. ProBioGen will support ImmunOs in the development of their biologics using its recently launched DirectedLuck Transposase technology and conducting large scale GMP manufacturing. ImmunOs has a pipeline of novel agents in development.
 
“We are pleased about this confidence in our expertise,” said Wieland Wolf, chief executive officer, ProBioGen. “It is our goal enabling ImmunOs to start clinical trials with this promising molecule in a timely manner. We are very passionate to develop a cell line and respective robust processes based on our innovative technologies to deliver their product with highest quality.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics